The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
The company also reported significant progress toward its internally defined Sustainable Development Goals
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
The initiative is focused on a problem that continues to plague cancer outcomes in India
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
Subscribe To Our Newsletter & Stay Updated
